Therapy-Related Acute Myeloid Leukemia Following HIV-Associated Lymphoma

In the highly active antiretroviral therapy era, an increasingly large number of HIV-infected patients are developing non—AIDS-defining cancers (NADCs). As patients survive longer, long-term therapy—related complications take on greater importance. Herein, we describe a patient with AIDS who present...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma & myeloma 2009-08, Vol.9 (4), p.316-319
Main Authors: Mani, Deepthi, Dorer, Russell K., Aboulafia, David M.
Format: Article
Language:English
Subjects:
Adult
AIDS
Alkylating agent
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Chromosome Aberrations
Chromosomes, Human, Pair 10 - genetics
Chromosomes, Human, Pair 11 - genetics
Cytogenetic Analysis
Fatal Outcome
Follow-Up Studies
Histone-Lysine N-Methyltransferase
Humans
Leukemia, Myeloid, Acute - chemically induced
Leukemia, Myeloid, Acute - diagnosis
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Lymphoma, AIDS-Related - diagnosis
Lymphoma, AIDS-Related - drug therapy
Lymphoma, AIDS-Related - genetics
Male
Myeloid-Lymphoid Leukemia Protein - genetics
Non-Hodgkin lymphoma
Non-Hodgkin's lymphoma
Topoisomerase inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the highly active antiretroviral therapy era, an increasingly large number of HIV-infected patients are developing non—AIDS-defining cancers (NADCs). As patients survive longer, long-term therapy—related complications take on greater importance. Herein, we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma. Bone marrow biopsy showed a moderately hypocellular marrow; 51% of the nucleated cells were blasts with myelomonocytic differentiation. Cytogenetic studies revealed an abnormal karyotype with deletion of the long arm of chromosome 11 (11q21) and 2 additional copies of the MLL gene attached to the short arms of chromosome 10 in 80% of the metaphase cells examined. With the diagnosis of therapy-related acute myeloid leukemia (AML) secured, he began induction chemotherapy with idarubicin and cytarabine. Two weeks later, he died of fungal septicemia and multiorgan failure. Through a literature search, we were able to identify 4 additional cases of therapy-related AML in AIDS patients following chemotherapy for lymphomas. The median age of these patients at the time of AML diagnosis was 39 years (range, 33–59 years), the median time from the treatment of lymphoma to AML was 18 months (range, 11–48 months), and the median survival following induction chemotherapy was 4 weeks (range, 2–16 weeks). With many HIV-infected patients surviving alkylator and topoisomerase inhibitor—based treatment and radiation therapy for AIDS-defining cancers and NADCs, long-term follow-up for therapy-related complications assumes greater importance.
ISSN:1557-9190
1938-0712
DOI:10.3816/CLM.2009.n.062